SBIR/STTR Research Award
Precision genomics for United States Air Force personnel using Cancer Risk B and Cancer Risk C
Award amount
$49,955Program and phase
SBIR · Phase IAward year
2022Award details
- Awarding agency
- Department of Defense
- Branch
- Air Force
- Recipient company
- Morgan and Mendel Genomics, Inc.
- Proposal award date
- 2021-11-03
- Contract end date
- 2022-02-07
- UEI
- JHNHD3R1TCT8
- Solicitation number
- X21.2
- Topic code
- AF212-CSO1
Research abstract
Morgan and Mendel Genomics (MMG) is a functional genomics company developing cutting edge science to identify genetic disruptions in human cells with high sensitivity and specificity, low cost, and rapid performance time. MMG’s two novel blood tests, Canc
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- Robust Predictor of Colon Cancer Risk
- Novel, rapid and accurate blood tests for detecting hereditary cancer risk
- Robust Predictor of Breast Cancer Risk
- Robust Predictor of Colon Cancer Risk
- Robust Predictor of Breast Cancer Risk
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- Monitoring Evolution of Coordinated Inauthentic Behavior
- Automated Target Recognition for Rapid Multitarget Grouping, Discrimination and Neutralization
- Composite Binder Enabling Higher Propellant Loading and Performance for Extended Range and Reduced Mass Missile Propulsion
- Video Based Assessment Capabilities and Human Performance Optimization
- Secure, BYOAD Enterprise Talk, Text, Video, and Data Transmission for Air Force Special Operations Command in Communications Denied/Degraded Environments
Research funding history
6 SBIR/STTR records share this UEI (2017–2022). Reported award amounts total $5,506,869. Reported amounts are not federal obligations.
Phases: Phase II, Phase I
Agencies: Department of Health and Human Services, Department of Defense